hemophilia

How Healthcare Spin-Offs are Affecting the IndustryJohn R. Washlick, Buchanan, Ingersoll & Rooney, and expert in healthcare system transactions and market consolidation, talks to Managed Healthcare Executive about healthcare spin-offs, what that means for the future of mergers and acquisitions, and advice for healthcare executives.
Groundbreaking gene therapies in store for hemophiliaTreatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
New hemophilia B gene therapy appears effectiveA recent trial showed that a single intravenous infusion of a vector expressing a high specific-activity factor IX gene safely produces a sustained, effective level of factor IX coagulant activity in patients with hemophilia B.
Treatment investigated to prevent blood-clotting disordersA new subcutaneous therapy could offer a promising solution to a bleeding disorder in both children and adults.
Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Bleeding disorders: When to worry, how to helpStudies have shown that 1 in 5 women who consult their doctor for heavy or prolonged bleeding during their periods actually have an underlying bleeding disorder.
New antibody eases hemophilia treatmentA new antibody eases treatment of severe hemophilia A.
New biologic to control bleeding for hemophilia B patientsAt the end of April, FDA approved a new biologic to help prevent and control bleeding in patients with hemophilia B who are 12 years and older. It also is approved for use in perioperative management in this patient population.
FDA approves NovoSeven RT for Glanzmann's thrombastheniaFDA approved coagulation factor VIIa [recombinant] (NovoSeven RT, Novo Nordisk), for the treatment of Glanzmann’s thrombasthenia, a rare genetic bleeding disorder.
FDA drug approvals: January 2014FDA approvals, complete response, fast-track designations, priority review, first-time generic approval